Treating women for Hodgkin lymphoma during pregnancy appeared safe and did not significantly affect maternal outcomes, according to results of a retrospective cohort study published in The Lancet Haematology.

“The most important message is that maternal prognosis is the same as in nonpregnant women,” Frédéric Amant, MD, PhD, professor of gynecologic oncology at Netherlands Cancer Institute in Amsterdam, told HemOnc Today. “There was some doubt, [because] there is always some chemodilution and the effect on efficacy has been poorly studied. However, we can now tell mothers and fathers that lymphoma treatment during pregnancy is possible, and not at the cost of inferior maternal survival.”